It is included on the 2026 WADA Monitoring Program alongside semaglutide, allowing WADA to gather data on GLP-1 receptor agonist use patterns ahead of a possible Prohibited List decision by late 2026 or 2027
Vial duration by dose But remember the 28-day rule
International Pharmacy Options Patients can access significant savings on FDA-approved medications through licensed Canadian pharmacies
10.1006/taap.2002.9450 120 YoonE.BabarA.ChoudharyM.KutnerM.PyrsopoulosN
Common side effects include: Cognitive slowing, including difficulties with memory, concentration, and word-finding Fatigue and drowsiness Dizziness and coordination problems Paraesthesia (tingling sensations, particularly in the hands and feet) Decreased appetite and weight loss Mood changes, including low mood, depression, and irritability More serious risks include: Metabolic acidosis topiramate inhibits carbonic anhydrase, which can reduce blood bicarbonate levels
Sermorelin is not a steroid or actual growth hormone